By Michael Macagnone ( November 3, 2016, 4:58 PM EDT) -- Novartis AG asked a Federal Circuit panel to set aside a Patent Trial and Appeal Board decision that invalidated its multiple sclerosis treatment Gilenya on Thursday, pushing the judges to find that the board can't disparage a prior art reference and then use it as a pillar of a decision to toss a patent....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.